A Biologic With Otologic Consequences: Analysis of Hearing Loss and Teprotumumab Using the FDA Adverse Event Reporting System
This study using FAERS data suggests an increased risk of OARs, specifically hearing loss, associated with teprotumumab. Increasing age was a significant predictor of OARs. Audiometric counseling and evaluation should be considered with teprotumumab therapy in Graves' orbitopathy patients, especially in older patients.
Authors
- Pauline P. Huynh (ORCID: https://orcid.org/0000-0001-5878-1442)
- Elias S. Saba (ORCID: https://orcid.org/0000-0001-6186-9912)
- Alexander Rivero (ORCID: https://orcid.org/0000-0002-2347-4917)
- Robert J. Peralta
- Jonathan Liang (ORCID: https://orcid.org/0009-0004-6510-9733)
Institutions
- Kaiser Permanente Oakland Medical Center (US)
Publication Details
- Journal
- Otology & Neurotology
- Published
- 2024-08-15
- DOI
- https://doi.org/10.1097/mao.0000000000004260
- Citations
- 3
- Primary Topic
- Ophthalmology and Eye Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.27